Table 2.
Characteristics of each group 6months after switching
| IDegAsp | IDegLira | p value | |
|---|---|---|---|
| Body weight, kg | 67.6 ± 15.3 | 71.7 ± 12.2 | 0.142 |
| BMI, kg/m2 | 25.3 ± 4.3 | 26.6 ± 4.2 | 0.218 |
| HbA1c, % | 8.5 ± 1.2 | 7.8 ± 0.9 | 0.003 |
| Total insulin dose, units (IQR) | 17 (12–23) | 14 (12–18) | 0.199 |
| Total insulin dose, units/kg (IQR) | 0.24 (0.19–0.33) | 0.21 (0.16–0.25) | 0.023 |
| Noninsulin antihyperglycemic agents, N (%) | |||
| Liraglutide dose, mg (IQR) | 0.50 (0.33–0.65) | ||
| Metformin | 18 (34.6) | 31 (79.5) | < 0.001 |
| Sulfonylurea | 17 (32.7) | 12 (30.8) | 1.000 |
| DPP-4 inhibitors | 36 (69.2) | 1 (2.6) | < 0.001 |
| Thiazolidinediones | 4 (7.7) | 3 (7.7) | 1.000 |
| Glinides | 10 (19.2) | 8 (20.5) | 0.783 |
| α-GIs | 16 (30.8) | 7 (17.9) | 0.251 |
| SGLT2 inhibitors | 21 (40.4) | 26 (66.7) | 0.008 |
Data are presented as mean ± standard deviation or median (interquartile range (IQR))
IDegAsp, Degludec/Aspart; IDegLira: Degludec/Liraglutide; BMI, body mass index; DPP-4, dipeptidyl peptidase 4; α-GIs, α-glucosidase inhibitors; SGLT2, sodium-glucose cotransporter 2